{"id":37637,"date":"1998-01-01T00:00:00","date_gmt":"1998-01-01T00:00:00","guid":{"rendered":"https:\/\/www.deberes.net\/tesis\/sin-categoria\/inmunoterapia-con-interferon-alfa-como-tratamiento-adyuvante-de-la-cirugia-en-pacientes-con-melanoma-maligno-cutaneo\/"},"modified":"1998-01-01T00:00:00","modified_gmt":"1998-01-01T00:00:00","slug":"inmunoterapia-con-interferon-alfa-como-tratamiento-adyuvante-de-la-cirugia-en-pacientes-con-melanoma-maligno-cutaneo","status":"publish","type":"post","link":"https:\/\/www.deberes.net\/tesis\/ciencias-medicas\/inmunoterapia-con-interferon-alfa-como-tratamiento-adyuvante-de-la-cirugia-en-pacientes-con-melanoma-maligno-cutaneo\/","title":{"rendered":"Inmunoterapia con interferon alfa como tratamiento adyuvante de la cirugia en pacientes con melanoma maligno cutaneo."},"content":{"rendered":"<h2>Tesis doctoral de <strong>  Paz Carreira Jos\u00e9 Manuel <\/strong><\/h2>\n<p>Para evaluar la eficacia cl\u00ednica y la toxicidad de dosis bajas (5mu) e intermedias (10mu) de interfer\u00f3n alfa 2b recombinante (rifn) como tratamiento de la cirug\u00eda en pacientes con melanoma maligno cut\u00e1neo (mmc), estad\u00edos i-iii de la ajcc, se llev\u00f3 a cabo durante los a\u00f1os 1986 a 1996 un programa terap\u00e9utico en el hospital juan canalejo. Se establecieron 2 grupos que, de forma aleatoria, recibieron rifn 5 o 10 mu\/d\u00eda\/sc durante 7 d\u00edas, seguidos de 5 \u00f3 10 mu bisemanales durante 2 a\u00f1os.  sesenta y dos pacientes, mediana de edad de 54 a\u00f1os y relaci\u00f3n var\u00f3n:mujer de 1:2 se incluyeron en el estudio:  35 recibieron 5mu y 27 10mu, con una mediana de seguimiento de 40 meses. La dosis de rifn no fue un predictor significativo de la sg (p=0.62) o de la sle (p=0.3). La probabilidad de sg y sle a 8 a\u00f1os es del 100% en pacientes en estad\u00edo i. El 70% de los pacientes recibieron m\u00e1s del 70% de la dosis prevista y menos del 5% de los pacientes presentaron toxicidad grados iii-iv.  mediante an\u00e1lisis multivariante: a) la ulceraci\u00f3n del tumor es el \u00fanico predictor significativo de la sg; b) el tiempo total de tratamiento con rifn, el estad\u00edo de la ajcc, el grosor de breslow y la ulceraci\u00f3n del tumor son factores pron\u00f3sticos significativos para la sle. Dosis bajas e intermedias de rifn alfa2b como tratamiento adyuvante de la cirug\u00eda obtienen una sle prolongada con una toxicidad aceptable y no difieren en t\u00e9rminos de sg, sle y toxicidad.<\/p>\n<p>&nbsp;<\/p>\n<h3>Datos acad\u00e9micos de la tesis doctoral \u00ab<strong>Inmunoterapia con interferon alfa como tratamiento adyuvante de la cirugia en pacientes con melanoma maligno cutaneo.<\/strong>\u00ab<\/h3>\n<ul>\n<li><strong>T\u00edtulo de la tesis:<\/strong>\u00a0 Inmunoterapia con interferon alfa como tratamiento adyuvante de la cirugia en pacientes con melanoma maligno cutaneo. <\/li>\n<li><strong>Autor:<\/strong>\u00a0  Paz Carreira Jos\u00e9 Manuel <\/li>\n<li><strong>Universidad:<\/strong>\u00a0 A coru\u00f1a<\/li>\n<li><strong>Fecha de lectura de la tesis:<\/strong>\u00a0 01\/01\/1998<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h3>Direcci\u00f3n y tribunal<\/h3>\n<ul>\n<li><strong>Director de la tesis<\/strong>\n<ul>\n<li>Luis Miguel Anton Aparicio<\/li>\n<\/ul>\n<\/li>\n<li><strong>Tribunal<\/strong>\n<ul>\n<li>Presidente del tribunal: Hugo Castro Malaspina <\/li>\n<li>Jeronimo Forteza Vila (vocal)<\/li>\n<li>Jorge Teijeiro Vidal (vocal)<\/li>\n<li>Jos\u00e9 Carlos Mill\u00e1n Calenti (vocal)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tesis doctoral de Paz Carreira Jos\u00e9 Manuel Para evaluar la eficacia cl\u00ednica y la toxicidad de dosis bajas (5mu) e [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[18576,155,9,1027,347,156],"tags":[98443,2937,1813,39160,52649,98442],"class_list":["post-37637","post","type-post","status-publish","format-standard","hentry","category-a-coruna","category-ciencias-clinicas","category-ciencias-medicas","category-oncologia","category-oncologia-clinica","category-patologia","tag-hugo-castro-malaspina","tag-jeronimo-forteza-vila","tag-jorge-teijeiro-vidal","tag-jose-carlos-millan-calenti","tag-luis-miguel-anton-aparicio","tag-paz-carreira-jose-manuel"],"_links":{"self":[{"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/posts\/37637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/comments?post=37637"}],"version-history":[{"count":0,"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/posts\/37637\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/media?parent=37637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/categories?post=37637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.deberes.net\/tesis\/wp-json\/wp\/v2\/tags?post=37637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}